Skip to main content

What are you looking for?

Write the name, title or any keyword related to what you are looking for and select which content category it belongs to.

A phase IIa, randomized, parallel, double-blind, Placebo Controlled Study to Evaluate the Efficacy and safety of enpatoran in dermatomyositis and polymyositis participants receiving standard of care.

  • Protocol code: MS200569_0041
  • EudraCT code: _
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Principal investigator:  Selva O'Callaghan, Albert
  • Research group:  Malalties sistèmiques
  • Service: Medicina Interna
  • Phase: Fase II
  • Recruiting: Closed
  • Status: Tancat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Seguridad cardiovascular de 2,4 mg de cagrilintida s.c. en combinación con 2,4 mg de semaglutida s.c. (CagriSema 2,4 mg//2,4 mg s.c.) una vez a la semana en participantes con obesidad y enfermedad cardiovascular establecida

  • Protocol code: NN9838-4942
  • EudraCT code: 2021-005855-35
  • Pathology: Malalties endocrines, nutricionals i metabòliques
  • Principal investigator:  Ciudin Mihai, Andreea
  • Research group:  Diabetis i metabolisme
  • Service: Endocrinologia
  • Phase: Fase III
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack//Estudio de fase III, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para demostrar la eficacia y la seguridad de milvexian, un inhibidor oral del factor XIa, para la prevención de accidentes cerebrovasculares después de un accidente cerebrovascular isquémico agudo o un accidente isquémico transitorio de alto riesgo.

  • Protocol code: 70033093STR3001
  • EudraCT code: No aplica
  • Principal investigator:  Molina Cateriano, Carlos
  • Research group:  Recerca en ictus
  • Service: Neurologia
  • Phase: Phase III
  • Recruiting: Open
  • Status: Open

Contact Form

I have read and accept the data protection policy *.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.
Year
2024
Data d'inici
Data de tancament
Grup de recerca
Descripció
20240009_Predoctoral Researcher Cardiovascular Diseases Group
Codi
2024-9
Reclutant
Inactiu
Year
2024
Data d'inici
Data de tancament
Descripció
20240008_Digital Transformation Director
Codi
2024-8
Reclutant
Inactiu
Year
2024
Data d'inici
Data de tancament
Grup de recerca
Descripció
20240005_Study coordinator / Data manager-Infectious Diseases Group.
Codi
2024-5
Reclutant
Inactiu
Year
2024
Data d'inici
Data de tancament
Descripció
20240006_Research Nurse-Physiology and Physiopathology of the digestive tract.
Codi
2024-6
Reclutant
Inactiu
Year
2024
Data d'inici
Data de tancament
Descripció
20230007_Support Technician in Research-Psychiatry, Mental Health and Addictions Research Group.
Codi
2024-7
Reclutant
Inactiu
Year
2024
Data d'inici
Data de tancament
Grup de recerca
Descripció
2024001_Laboratory technician - Neurovascular diseases group
Codi
2024-1
Reclutant
Inactiu
Year
2024
Data d'inici
Data de tancament
Descripció
Personnel Administration Officer/ Coordinator_2024003
Codi
2024-3
Reclutant
Inactiu
Year
2024
Data d'inici
Data de tancament
Descripció
2024004_Study Coordinator
Codi
2024-4
Reclutant
Inactiu
Year
2023
Data d'inici
Data de tancament
Descripció
Project manager _ Group in Urology
Codi
2023-473
Reclutant
Inactiu
Year
2023
Data d'inici
Data de tancament
Grup de recerca
Descripció
2023470_ Bioinformatic Technician
Codi
2023-470
Reclutant
Inactiu
Year
2023
Data d'inici
Data de tancament
Descripció
IT Project Manager (Health – Hospital)
Codi
2023-471
Reclutant
Inactiu
Year
2023
Data d'inici
Data de tancament
Descripció
International Pre-Award Research Manager_20230469
Codi
2023-469
Reclutant
Inactiu
Year
2023
Data d'inici
Data de tancament
Descripció
Business Development Team Lead
Codi
2023-468
Reclutant
Inactiu
Year
2023
Data d'inici
Data de tancament
Grup de recerca
Descripció
Senior Researcher in Bioinformatics Rheumatology Research Group
Codi
2023-465
Reclutant
Inactiu
Year
2023
Data d'inici
Data de tancament
Grup de recerca
Descripció
Laboratory Technician Diagnostic Nanotools Research Group
Codi
2023-466
Reclutant
Inactiu
Year
2023
Data d'inici
Data de tancament
Grup de recerca
Descripció
Senior PostDoc – Development of malaria point-of-care Diagnostic Nanotools Research Group
Codi
2023-467
Reclutant
Inactiu
Year
2023
Data d'inici
Data de tancament
Descripció
Clinical Researcher-Research Group on Status Epilepticus and Acute Seizures.
Codi
2023-461
Reclutant
Inactiu